{"product_id":"es1766","title":"BCSC-1 rabbit pAb","description":"\u003cstrong\u003eApplications:\u003c\/strong\u003e WB;ELISA\u003cbr\u003e\u003cstrong\u003eReactivity:\u003c\/strong\u003e Human;Rat;Mouse;\u003cbr\u003e\u003cstrong\u003eSource:\u003c\/strong\u003e Rabbit\u003cbr\u003e\u003cstrong\u003eDilution:\u003c\/strong\u003e Western Blot: 1\/500 - 1\/2000. ELISA: 1\/20000. Not yet tested in other applications.\u003cbr\u003e\u003cstrong\u003eImmunogen:\u003c\/strong\u003e The antiserum was produced against synthesized peptide derived from human LHR2A. AA range:371-420\u003cbr\u003e\u003cstrong\u003eStorage_stability:\u003c\/strong\u003e -20°C\/1 year\u003cbr\u003e\u003cstrong\u003eClonality:\u003c\/strong\u003e Polyclonal\u003cbr\u003e\u003cstrong\u003eIsotype:\u003c\/strong\u003e IgG\u003cbr\u003e\u003cstrong\u003eConcentration:\u003c\/strong\u003e 1 mg\/ml\u003cbr\u003e\u003cstrong\u003eObserved_band(KD):\u003c\/strong\u003e 86kD\u003cbr\u003e\u003cstrong\u003eHuman_gene_id:\u003c\/strong\u003e 4013\u003cbr\u003e\u003cstrong\u003eHuman_swiss_prot_no:\u003c\/strong\u003e O00534\u003cbr\u003e\u003cstrong\u003eSubcellular_location:\u003c\/strong\u003e nucleus,nucleoplasm,\u003cbr\u003e\u003cstrong\u003eOther_name:\u003c\/strong\u003e VWA5A; BCSC1; LOH11CR2A; von Willebrand factor A domain-containing protein 5A; Breast cancer suppressor candidate 1; BCSC-1; Loss of heterozygosity 11 chromosomal region 2 gene A protein\u003cbr\u003e\u003cstrong\u003eBackground:\u003c\/strong\u003e VWA5A (von Willebrand factor A domain containing 5A), also known as BCSC-1 (breast cancer suppressor candidate 1) or LOH11CR2A (loss of heterozygosity 11 chromosomal region 2 gene A protein), is a 786 amino acid protein containing one VIT domain and one VWFA domain. VWA5A is expressed at low levels in various tissues, with no expression found in 80% of tumor cell lines. Likely acting as a tumor suppressor gene, deletion of VWA5A leads to loss of heterozygosity (LOH) in breast and ovarian tumors, and may have an important role as a potential gene therapy target. Abnormal expression of VWA5A may lead to an increase in adhesion of CNE-2L2 cells associated with an increase in expression of E-cadherin, alpha-catenin, and p53, resulting in a decrease of malignant activity in cells with ectopic expression of VWA5A. Existing as four alternatively spliced isoforms, the gene encoding VWA5A maps to human chromosome 11q24.2.","brand":"ELK Biotechnology","offers":[{"title":"50μL","offer_id":50411146707224,"sku":"ES1766","price":250.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0590\/5652\/1400\/files\/ES1766-c-1.jpg?v=1751072048","url":"https:\/\/danabiosci.com\/products\/es1766","provider":"Dana Bioscience","version":"1.0","type":"link"}